KemPharm Inc. (KMPH)

2.54 +0.19 (+8.085%)

IEX Real-Time Price

November 16, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 2.35

Price Open 2.34

Volume: 137,436

Avg Volume: 342,667

Market Cap: 67.2M

P/E Ratio -0.69

52 Wk Range 2.001-8.4



KMPH Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
15.76M
424,005
0.96
2.69%

2018-09-28
15.76M
1.15M
13.64
7.33%

2018-09-14
15.76M
1.34M
25.13
8.48%

2018-08-31
15.76M
1.35M
19.07
8.58%




KMPH Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-08
Q3 2018
AMC
-0.74 (3)
-0.94
-0.20

2018-08-09
Q2 2018
AMC
-0.98 (3)
-0.91
0.07

2018-05-10
Q1 2018
AMC
-0.70 (2)
-1.11
-0.41

2018-05-09
Q1 2018
N/A
-0.67 (2)
0.00
0.00

News

KemPharm (KMPH) CEO Travis Mickle on Q3 2018 Results - Earnings Call Transcript (2018-11-08 21:18 SeekingAlpha)

KemPharm (KMPH) Q3 2018 Earnings Conference Call November 08, 2018 04:30 PM ET Executives Joshua Drumm - Investor Relations. Travis Mickle - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Analysts Daniel Busby - RBC Capital Markets Esther …

 


Statistics

Shares Outstanding: 26.46M

Top 15 Institution Percent: 49.50

Price To Sales: N/A

Price To Book: 162.74

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -158.48

Return On Equity: 86.23

Profit Margin: N/A

Price History

Beta: 0.86

50-day Moving Avg: 3.33

200-day Moving Avg: 5.18

YTD Change: -38.80

5-day Change: 3.25

1-month Change: 2.01

3-month Change: -46.53

6-month Change: -58.36

1-year Change: -33.16

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: KemPharm Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.kempharm.com

KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs.